Hala Elnakat Thomas
Overview
Explore the profile of Hala Elnakat Thomas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
295
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stefely J, Zhang Y, Freiberger E, Kwiecien N, Thomas H, Davis A, et al.
Autophagy
. 2020 Jan;
16(12):2219-2237.
PMID: 31971854
Macroautophagy/autophagy is suppressed by MTOR (mechanistic target of rapamycin kinase) and is an anticancer target under active investigation. Yet, MTOR-regulated autophagy remains incompletely mapped. We used proteomic profiling to identify...
2.
Langevin S, Kuhnell D, Orr-Asman M, Biesiada J, Zhang X, Medvedovic M, et al.
RNA Biol
. 2019 Jan;
16(1):5-12.
PMID: 30604646
Ultracentrifugation remains the gold standard for isolation of small extracellular vesicles (sEV), particularly for cancer applications. The objective of this study was to determine if a widely used ultracentrifugation protocol...
3.
Thomas H, Zhang Y, Stefely J, Veiga S, Thomas G, Kozma S, et al.
Cell Rep
. 2018 Aug;
24(9):2404-2417.e8.
PMID: 30157433
Cells adapt to nutrient and energy deprivation by inducing autophagy, which is regulated by the mammalian target of rapamycin (mTOR) and AMP-activated protein kinases (AMPKs). We found that cell metabolism...
4.
Veiga S, Ge X, Mercer C, Hernandez-Alvarez M, Thomas H, Hernandez-Losa J, et al.
Clin Cancer Res
. 2018 Apr;
24(15):3767-3780.
PMID: 29691292
Hepatocellular carcinoma (HCC) ranks second in cancer mortality and has limited therapeutic options. We recently described the synergistic effect of allosteric and ATP-site competitive inhibitors against the mTOR for the...
5.
Chauhan A, Arnold S, Kolesar J, Thomas H, Evers M, Anthony L
Oncotarget
. 2018 Mar;
9(18):14738-14740.
PMID: 29581877
Introduction: Large cell neuroendocrine carcinomas (LCNEC) are a group of rare high grade neuroendocrine tumors that often behave clinically like small cell carcinoma (SCLC) and are treated as such. No...
6.
Wise-Draper T, Moorthy G, Salkeni M, Karim N, Thomas H, Mercer C, et al.
Target Oncol
. 2017 Mar;
12(3):323-332.
PMID: 28357727
Background: The combination of everolimus and the imidazoquinoline derivative, BEZ235 (dactolisib), a dual PI3K/mTOR inhibitor, demonstrated synergy in a preclinical model. Objective: To establish clinical feasibility, a phase Ib dose-escalation...
7.
Liu H, Feng X, Ennis K, Behrmann C, Sarma P, Jiang T, et al.
Cell Rep
. 2017 Mar;
18(9):2088-2095.
PMID: 28249155
Genetic S6K1 inactivation can induce apoptosis in PTEN-deficient cells. We analyzed the therapeutic potential of S6K1 inhibitors in PTEN-deficient T cell leukemia and glioblastoma. Results revealed that the S6K1 inhibitor...
8.
Thomas H, Mercer C, Carnevalli L, Park J, Andersen J, Conner E, et al.
Sci Transl Med
. 2012 Apr;
4(139):139ra84.
PMID: 22539746
Hepatocellular carcinoma (HCC) affects more than half a million people worldwide and is the third most common cause of cancer deaths. Because mammalian target of rapamycin (mTOR) signaling is up-regulated...